A Cross-Sectional Comparison of Druggable Mutations in Primary Tumors, Metastatic Tissue, Circulating Tumor Cells, and Cell-Free Circulating DNA in Patients with Metastatic Breast Cancer: The MIRROR Study Protocol

• DOI: 10.2196/resprot.6024
• Publication Date: 2016-08-16T09:00:07Z
• Authors: Milagros Gonzalez...; Antoni C Picornell; Enrique L Alvarez; Miguel Martin
• Keywords: Druggability; Circulating tumor cell

Characterization of the driver mutations in an individual metastatic breast cancer (MBC) patient is critical to selecting effective targeted therapies. Currently, it believed that limited efficacy many drugs may be due expansion drug resistant clones with different genotypes were already present primary tumor. Identifying genomic alterations these clones, and introducing combined or sequential regimens, could lead a significant increase currently available therapies.The objective this study assess concordance/discordance between tumor tissue MBC patients. Secondary objectives include comparing profiles circulating cells (CTCs) free DNA (cfDNA) from peripheral blood those for each patient, evaluating signaling pathways are relevant disease, testing feasibility liquid biopsy as translational laboratory tool clinical practice.The multicenter, transversal, observational MIRROR ongoing three participating hospitals. All consecutive patients confirmed by radiologic findings will screened eligibility, either at first relapse if regrowth occurs while on treatment disease.Patient recruitment ongoing. To date, 41 have complete set samples (plasma, CTCs, formalin-fixed, paraffin-embedded tumor). However, none undergone nucleic acids extraction deep sequencing.The results influence practical management MBC, provide clues clinicians towards better stratification patients, resulting more selective less toxic treatments. Additionally, found tissues similar detected CTCs and/or cfDNA, biopsies prove convenient, non-invasive, easily accessible source material analysis other aberrations MBC.ClinicalTrials.gov NCT02626039; https://clinicaltrials.gov/ct2/show/NCT02626039 (Archived WebCite http://www.webcitation.org/6jlneVyoz).